Introduction {#S0001}
============

One of the global concerns is the increasing trend toward antimicrobial resistance and the consequent lack of efficient antimicrobials.[@CIT0001] Enhanced resistance to antimicrobials is a true menace to communal health, and realization of the systematic origin of antimicrobial resistance is important to cope with this public health menace.[@CIT0002] Also, antibiotic-resistant infections cause more morbidity and mortality and are associated with more health-care expenses.[@CIT0003] On the other hand, the availability of second-line antibiotics in developing countries diminishes the usage of next-generation antibiotics and causes more morbidity and mortality after antibiotic-resistant infections.[@CIT0004]

Hospital-acquired infections emerging at least 48--72 h after admission of the patient are named nosocomial infections (NIs) and present a big threat for patients all over the world.[@CIT0005],[@CIT0006] Three kinds of infections that cause more than 60% of NIs are urinary tract infections, pneumonia, and primary bloodstream infections (BSIs), that are usually associated with using medical devices such as ventilators and catheters.[@CIT0007] Among the pathophysiological mechanisms that contribute to the emerging NIs, bacterial colonization and immunodeficiency are the main culprits.[@CIT0005]

Enterococci are normal flora of the gastrointestinal tract. When a hospitalized patient is treated with broad-spectrum antibiotics, Enterococci are eliminated which leads to a decrease in the thickness of the protective gastrointestinal mucus layer. This enables unusual outgrowth of hospital-associated Enterococcal clones which are resistant to antibiotics.[@CIT0008]--[@CIT0012] *Enterococcus* species have a broad range of resistance genes, and are able to exchange the resistance genes.[@CIT0013] Enterococci are the third common cause of NIs and health-care-associated BSIs[@CIT0014]--[@CIT0016] and have been estimated to be responsible for 25--50% of the mortality rate among hospitalized patients.[@CIT0017]--[@CIT0022] Also, simultaneous multiple resistance mechanisms lead to the emergence of multiresistant or pan-resistant Enterococci that do not respond to the common first-line antibiotics, leading to amplified morbidity and mortality rates and eventually more financial burdens on hospitals and patients.[@CIT0023]

Among *Enterococcus* species, two major species (*Enterococcus faecalis*and *Enterococcus faecium*) are particularly pathogenic for humans: 85--90% of Enterococci infections are caused by *E. faecalis*, whereas 5--10% are caused by *E. faecium*;[@CIT0024] however, *E. faecium* BSI has higher rates of antibiotic resistance and mortality than *E. faecalis* BSI.[@CIT0025],[@CIT0026] Some of the important hospitalized infections which are life-threatening are BSIs because of vancomycin-resistant Enterococcal (VRE) species.[@CIT0016],[@CIT0027]--[@CIT0029]

In laboratory animals such as mice, the usage of antibiotics including cefoxitin, ceftriaxone, ampicillin, and vancomycin causes outgrowth of drug-resistant *E. faecium* isolates.[@CIT0030] Moreover, *E. faecium* is one of the ESKAPE pathogens (*E. faecium, Staphylococcus aureus, Klebsiella pneumoniae, Acinetobacter baumannii, Pseudomonas aeruginosa*, and *Enterobacter*species) and along with *E. faecalis*is responsible for the most *Enterococcus* infections.[@CIT0013] It is worth mentioning that pathogenic *E. faecalis* strains can produce cytolysin, which exacerbates the toxicity caused by the infections and leads to a fivefold extreme threat of death in nosocomial bacteremia.[@CIT0031]--[@CIT0033]

According to our systematic review, there is no comprehensive study regard antibiotic resistance in isolated Enterococci. There are some review articles with limited data on the domain of special countries or exclusive to special antibiotics, such as vancomycin, linezolid, and tigecycline.[@CIT0034]--[@CIT0038] The goal of this systematic review is to survey the frequency of antibiotic resistance to some common antibiotics in Enterococci isolated from blood isolates of hospitalized patients worldwide. Consequently, these data could be helpful in tackling drug resistance problems and illuminating the best antibiotic options that are effective for the treatment of the infections caused by Enterococci.

Methods {#S0002}
=======

Sources of information and search strategies {#S0002-S2001}
--------------------------------------------

From January 1, 2000 to May 20, 2018, two reviewers (SMJS and AP) searched systematically all publications including antibiotic resistance in Enterococci isolated from NIs via Medline (via PubMed), Embase, and Cochrane Library independently with the MeSH terms "*Enterococcus faecalis*", "*Enterococcus faecium*", "drug resistance", "sepsis", and "antimicrobial resistance". MeSH terms were combined with text word searches that included "*E. faecium", "E. faecalis*", "septicemia", "bloodstream", "antibiotic(s)", and their synonyms. In addition, we searched related reviews and selected articles, citation lists (backward citation), and references (forward citation) by hand and corresponded with authors (recommended by the Cochrane guideline).[@CIT0039] We did not contact the expert authors regarding previous experiences.[@CIT0040],[@CIT0041] We conducted our study according to the systematic review of prevalence PRISMA guidelines.[@CIT0042]

Eligibility {#S0003}
===========

Inclusion criteria {#S0003-S2001}
------------------

All original cross-sectional articles published in English and other languages, without language restriction, on different antibiotic resistance prevalence in blood-isolated Enterococci strains with standard laboratory tests were included for further analysis. All strains were isolated from hospitalized patients. We found studies in languages other than English that were translated using Google Translate (<http://translate.google.com>). Standard laboratory tests for determination of *E. faecium* and *E. faecalis* drug resistance included phenotypical microbiological methods such as the disk diffusion method, minimum inhibitory concentration, VITEK 2 system (bioMérieux), plate/replicator method, Isosensi test agar (Oxoid), and Trek Diagnostic Systems Inc. (Westlake, OH, USA). Additionally, molecular methods such as PCR, real-time PCR, PCR-restriction fragment length polymorphism, and sequencing assays had been used as the detection method in some studies.

Exclusion criteria {#S0003-S2002}
------------------

Articles were excluded from review for any of the following reasons: No accessible full text, or insufficient data in the abstract.Studies which just focused on treatment, without any clear report of drug resistance prevalence.Case report and review studies.Isolates were from healthy people as colonization.Surviving in special disease groups (eg, HIV-positive or any other immunodeficient patients).Isolated from surfaces, food, soil, animal, or sewage origins.Studies which had our aimed keywords, but without relevant data.Reports from mixed-infection patients without any Enterococci drug resistance pattern.Studies that investigated the prevalence of antibiotic resistance in vancomycin linezolid, ampicillin, and gentamycin-resistant Enterococci.The total number of Enterococci was not specified.

Data extraction and data collection {#S0003-S2003}
-----------------------------------

Data were extracted by two reviewers (SMJS and AP) independently and results were checked by a third reviewer (AH). Contradictions among the investigators were discussed to obtain agreement. The following data were extracted: name of first author, publication time, sample size, time and location of the study, type of participants, numbers of *E. faecium* and *E. faecalis* culture-positive isolates, and number of resistance *E. faecium* and *E. faecalis* isolated for each of the antibiotics. Studies identified by the search strategy were reviewed for eligibility based on the title and abstract by two investigators (SMJS and AP). Full manuscripts of the papers kept based on the title and abstract were assessed by the same investigator. Studies identified by the search strategy were reviewed for eligibility based on the title and abstract by one investigator (SMJS). Full manuscripts of the papers were kept based on the title and abstract and were further assessed by the same investigator. For both steps, a 10% random sample was assessed by a second investigator and was compared to the assessment of the first reviewer (AP). Extracted data were further reviewed and inconsistencies in the assessments discussed, and disagreements were resolved by consensus.

Quality assessment {#S0003-S2004}
------------------

Quality assessment of studies was performed by two reviewers independently according to the modified Critical Appraisal Checklist recommended by the Joanna Briggs Institute,[@CIT0043] and disagreements were resolved by consensus. The checklist is composed of 9 questions that reviewers addressed for each study. The "Yes" answer for each question received a score of 1. Thus, final scores for each study could range from 0 to 9 ([[Table S1]{.ul}](https://www.dovepress.com/get_supplementary_file.php?f=206084.pdf)).

Meta-analysis approach {#S0003-S2005}
----------------------

Cleaning data and preparing them for analysis were done in Microsoft Excel 2010 (Microsoft Corporation, Redmond, WA, USA) and further analyses were carried out via Comprehensive Meta-Analysis Software Version 2.0 (Biostat, Englewood, NJ, USA). Determination of heterogeneity among the studies was undertaken using the chi-squared test (Cochran's Q) to assess the appropriateness of pooling data. Depending on the heterogeneity test, we used either random or fixed effect models for pooled prevalence of drug resistance. In the case of high heterogeneities (I^2^\>50%), a random effect model (heterogeneity) was applied, while in low heterogeneities (I^2^\<50%) a random effect model was used.[@CIT0044] The pooled resistance prevalence of each antibiotic was calculated. We also used the Begg's and Egger's test based on the symmetry assumption described for publication bias. The point estimates of the effect size and the resistance prevalence of each antibiotic, along with its 95% CI, were estimated for each study. Complementary analyses such as time trend, continent, and subgroup pooled prevalence were generated for countries and WHO regional offices.

Result {#S0004}
======

Study selection {#S0004-S2001}
---------------

We retrieved about 24,862 studies in a systematic search and excluded 1016 after the ﬁrst screening. Finally, 291 studies were included in the meta-analysis ([Figure 1](#F0001){ref-type="fig"}). Characteristics of the selected articles are summarized in Table S1. Of the 291 included studies, 103 of them reported antibiotic susceptibility test with the minimum inhibitory concentration method and 100 of them reported by the disc diffusion method. A total of 143 studies interpreted and reported antimicrobial sensitivity tests according to Clinical and Laboratory Standards Institute (CLSI) guidelines, 22 were according to National Committee for Clinical Laboratory Standards (NCCLS), 6 were according to the Committee of the French Society of Microbiology (CASFM), 5 were according to the European Committee on Antimicrobial Susceptibility (EUCAST), 2 were according to the British Standard for Antimicrobial Chemotherapy (BSAC), and 108 were not reported. There were no differences in resistance between studies that did report the use of antimicrobial sensitivity test with different guidelines and those that did not.Figure 1Flow diagram of the literature search and study selection (PRISMA flow chart).

The prevalence of antibiotic resistance in blood isolates of *E. faecalis* {#S0004-S2002}
--------------------------------------------------------------------------

Of the 291 included studies, 125 studies reported the prevalence of *E. faecalis* antibiotic resistance in blood isolates. The total pooled number of *E. faecalis blood* isolates was 24,913. Linezolid had the lowest prevalence rate at 0.6% (95% CI: 0.3--15) while quinupristin/dalfopristin had the highest rate at 97% (95% CI: 89--99.2) ([Table 1](#T0001){ref-type="table"}).Table 1Prevalence of antibiotic resistance in blood-isolated *Enterococcus* spp.Antibiotic*Enterococcus faecalisEnterococcus faeciumEnterococcus* spp.Pooled prevalence (%) (95% CI)n/NN of studiesPooled prevalence (%) (95% CI)n/NN of studiesPooled prevalence (%)\
(95% CI)n/NN of studiesVancomycin1.6 (1.4--2.5)336/14,7418810 (8--13)1762/12,6951086.6 (5.7--7.7)3029/34,708245Gentamicin36.5 (33--40)7167/20,1638946.5 (39--45)2019/41965337.5 (35--40)11,284/29,958181Ampicillin4 (2.3--7)921/11,0474878 (73--82.5)2979/37474543.5 (39.3--47.8)5678/20,870133Teicoplanin2 (1.2--3)215/70314114.5 (9.5--22)488/2246366 (5--6.5)1285/14,876110Linezolid0.6 (0.3--1)52/8762341.7 (1--2.8)34/3293340.9 (0.7--1.3)104/17,947100Ciprofloxacin43.5 (36--51)2855/68404075 (69--80)1944/25133257.5 (53--61.7)6530/12,66699Streptomycin35 (30.5--40)2805/80974250.5 (42.2--59)1336/23773538.53 (4.5--45.5)5192/13,20788Erythromycin70 (65--74)3952/55532784 (79--88)1661/19772673.7 (70--77)6969/10,87469Penicillin18 (12--26.5)868/53822685.5 (81--89)1656/19262461 (55.5--66)2900/843766Chloramphenicol30 (23.3--38)543/18381917.5 (11.5--26)113/6571426 (22.3--30)1355/541962Levofloxacin27.5 (22--34)1511/50451779.3 (72.6--84.7)1182/14841745 (40.7--49.6)4397/10,43754Quinupristin/dalfopristin97 (89--99.2)2170/247998 (4.6--13.8)225/19722344.5 (36--53)4435/786250Tetracycline81.5 (74.6--87)2822/34972159 (49.2--68)651/11941666 (62--70)4951/702848Daptomycin0.2 (0.1--0.5)0/3636110.6 (0.2--1.2)0/1308120.4 (0.3--0.6)2/870440Nitrofurantoin2 (0.8--5.6)77/24941443 (30.5--56.7)455/10031421.5 (15.7--28.5)703/440133Amoxicillin/clavulanic acid3.2 (0.5--18.5)8/400554 (35--72)110/207529.5 (19.5--41.5)183/97619Imipenem5 (0.6--21.2)119/1076679.3 (57.2--91.7)548/669545 (25.5--66)731/232716Tigecycline0.5 (0.1--1.7)1/73841 (0.2--4.5)3/49240.5 (0.2--1)4/340411Norfloxacin23.5 (13--38.6)122/434370.3 (40.89.3)114/144357.3 (49.6--64.7)446/90210Amikacin21.5 (17--27.3)51/236231 (20.5--45.5)19/62223.3 (19--28.3)133/63310Linezolid0.9 (0.1--7)1/53740.9 (0.2--4.3)0/17231 (0.1--2.7)2/8349

Out of the six WHO original offices, America had the lowest prevalence of antibiotic resistance at 0.3% (95% CI: 0.2--0.6) for linezolid ([Table 2](#T0002){ref-type="table"}). [Table 3](#T0003){ref-type="table"} shows the pooled prevalence of the most important antibiotic resistance of blood-isolated *E. faecalis* from 2000--2016. Most of the antibiotics were subject to increased drug resistance of up to more than twofold. [Figure 2](#F0002){ref-type="fig"} demonstrates the time trend of *E. faecalis* vancomycin resistance prevalence by WHO regional offices. American, European, and Western Pacific countries showed the lowest level of vancomycin resistance with totally decreasing resistance prevalence in this period of time. However, South-East Asia and Eastern Mediterranean countries showed the highest level of vancomycin resistance with an increasing trend in resistance prevalence at the same time. [Figure 3](#F0003){ref-type="fig"} presents the pooled prevalence of *E. faecalis* vancomycin resistance by country. Sweden had the lowest prevalence at 0.2%, while Japan and Nepal had the highest prevalence at 18% and 11%, respectively.Table 2Prevalence of antibiotic resistance in blood-isolated *Enterococcus* spp. by WHO regional officesWHO regional officeAmericaAfricaEuropeSouth-East AsiaWestern PacificEastern MediterraneanAntibioticPooled prevalence (%)\
(95% CI)N of studyPooled prevalence (%) (95% CI)N of studyPooled prevalence (%) (95% CI)N of studyPooled prevalence (%) (95% CI)N of studyPooled prevalence (%) (95% CI)N of studyPooled prevalence (%) (95% CI)N of study*Enterococcus faecalis*Vancomycin4.5 (3--7)91 (0.1--7)21 (0.8--1.6)484 (2--7.2)110.6 (0.1--4.6)75 (2.6--9)11Gentamicin30.5 (28--33)851 (41.5--60.5)236 (31--41)4943 (31--52)1243.7 (33.7--54)732.2 (25.5--40)11Ampicillin1.5 (1--2)91 (0.1--7)21.5 (0.6--3)1350 (34.7--65)100.4 (0.2--1)711.7 (6.7--19.6)11Teicoplanin2.5 (1.2--5.5)70.6 (0--9)11 (0.6--1.7)174 (0.8--19)64.2 (2--9)14 (2.5--6.5)9Linezolid0.3 (0.2--0.6)83.6 (0.5--21.5)10.4 (0.2--0.9)92 (0.2--22)30.5 (0.2--1.7)71.5 (0.4--6)6*Enterococcus faecium*Vancomycin10.5 (25.5--57)101.3 (0.1--17)16.5 (5--8.6)716 (2--15.3)1020.5 (12--33)723.2 (11--42.3)11Gentamicin28 (15--45.3)861.5 (45.5--75.3)142 (28--57.5)1749.7 (35.6--64)1265.5 (53.2--76)739 (20--62)10Ampicillin81.5 (76.5--85.5)995 (81.7--98.7)183.5 (78--88)1450.5 (36--65)986 (79--91)764.5 (49.7--77)7Teicoplanin29 (14--51)71.3 (0.1--17)18 (2.5--22)128 (2.5--22)721 (11--37)120 (8.5--39.5)10Linezolid0.8 (0.4--2)8----1.3 (0.7--2.5)104 (2--9)41.5 (0.3--7)73 (1.2--7.7)7 Table 3Prevalence of antibiotic resistance in blood-isolated *Enterococcus*spp. by study time groupsStudy year2000--20052005--20102010--2016AntibioticPooled prevalence (%) (95% CI)n/NN of studiesPooled prevalence (%) (95% CI)n/NN of studiesPooled prevalence (%) (95% CI)n/NN of studies*Enterococcus faecalis*Vancomycin1 (0.5--2)52/5148252.2 (1.5--3.2)199/6401372.7 (1.5--5)85/308424Gentamicin36.5 (28.5--45.5)1476/37902139.7 (34--45.5)1910/49052334.5 (30--39)3726/11,36043Ampicillin4 (1.7--9)521/3753172 (0.7--6)143/4832149 (4--21)257/235415Teicoplanin0.9 (0.4--2)7/146891.8 (0.9--36)160/4020194.4 (2.5--8)55/147213Linezolid0.3 (0.1--0.8)1/154360.4 (0.1--1)14/5020152 (0.8--5.5)43/218013*Enterococcus faecium*Vancomycin8.2 (5--12.5)166/1861249 (6.5--12.5)1232/96746222 (14--33)364/112121Gentamicin42.5 (28--58.5)547/14472044 (34--54)806/16482057.5 (42--72.5)642/106212Ampicillin74.5 (65--82.5)826/11161681 (75--85.5)1404/16921776.5 (62--87)712/90011Teicoplanin11.2 (7--17.7)44/454913 (6.5--25.5)257/11771524.5 (12--43.5)187/57611Linezolid0.8 (0.3--2.2)0/70971.6 (0.9--2.8)14/1722173 (1--8)20/86210 Figure 2Time trend meta-analysis: prevalence of vancomycin resistance in blood-isolated *Enterococcus faecalis* by WHO regional offices.Figure 3Global prevalence of vancomycin resistance in blood-isolated *Enterococcus faecalis.*

The prevalence of antibiotic resistance in blood isolates of *E. faecium* {#S0004-S2003}
-------------------------------------------------------------------------

Of the 291 included studies, 114 studies reported the prevalence of *E. faecium* antibiotic resistance in blood isolates. The total pooled number of *E. faecium blood* isolates was 13,238. Tigecycline and linezolid had the lowest prevalence at 1% (95% CI: 0.2--4.5) and 1.7% (95% CI: 1--2.8), respectively; while penicillin had the highest prevalence of 85% (95% CI: 81--89) ([Table 1](#T0001){ref-type="table"}).

Of the WHO original offices, America had the lowest prevalence of antibiotic resistance at 0.8% (95% CI: 0.4--2) for linezolid ([Table 2](#T0002){ref-type="table"}). [Table 3](#T0003){ref-type="table"} describes the pooled prevalence of the most important antibiotic-resistant blood-isolated *E. faecium* from 2000--2016. Most of the antibiotics were subject to increased drug resistance of up to more than twofold, in particular vancomycin, whose time trend of resistance in *E. faecium* by WHO regional offices is described in [Figure 4](#F0004){ref-type="fig"}. [Figure 5](#F0005){ref-type="fig"} shows the pooled prevalence of *E. faecium* vancomycin resistance by country. The Netherlands had the lowest prevalence at 0.1%, while Brazil had the highest prevalence at 67%. [[Table S2]{.ul}](https://www.dovepress.com/get_supplementary_file.php?f=206084.pdf)--[[S43]{.ul}](https://www.dovepress.com/get_supplementary_file.php?f=206084.pdf) demonstrate the prevalence of drug resistance in *E. faecalis* and *E. faecium* for each antibiotic with more detail.Figure 4Time trend meta-analysis: prevalence of vancomycin resistance in blood-isolated *Enterococcus faecium* by WHO regional offices.Figure 5Global prevalence of vancomycin resistance in blood-isolated *Enterococcus faecium.*

Discussion {#S0005}
==========

This study illuminates the high rate of antibiotic resistance in Enterococcal bloodstream isolates in most regions of the world, especially in Eastern Mediterranean countries. Based on our findings, the prevalence of vancomycin-resistant *E. faecium* in BSIs is significantly high, especially in Eastern Mediterranean countries, which is an outstanding warning in treatment and control of this bacterium. Our findings, summarized in [Table 1](#T0001){ref-type="table"}, revealed that the resistance level to the most common treatments was significantly higher in *E. faecium* compared to *E. faecalis* in Enterococcal infections. Inherently, the antibiotic resistance rate in *E. faecium* is higher than in *E. faecalis*; specifically, high levels of resistance in *E. faecium* pathogenic types to ampicillin, vancomycin, and high-level aminoglycosides are documented. Therefore, treatment of the infections caused by these species is considered a serious problem that requires more precise treatment strategies. Quinupristin/dalfopristin combination is a member of streptogramin antibiotics that is broadly effective against VRE in Europe and the USA.[@CIT0045] Based on this study the pooled prevalence of resistance to quinupristin/dalfopristin was significantly higher in *E. faecalis*, which is in concord with previous publication results.[@CIT0046]

We observed that resistance to linezolid, daptomycin, and tigecycline was nearly at the same level for *E. faecalis* and *E. faecium* (pooled prevalence ≤1%), confirming that tigecycline and linezolid are effective against these species in low concentrations.[@CIT0047] Moreover, in our review, the lowest resistance in *E. faecalis* appeared to be to nitrofurantoin, amoxicillin/clavulanic acid, ampicillin, and imipenem which are critical in the treatment process.

Out of the six WHO original offices, America had the lowest prevalence of antibiotic resistance at 0.3% (95% CI: 0.2--0.6) for linezolid.

Based on our findings in America, in comparison with African countries, the least resistance to linezolid and gentamicin was seen in *E. faecium* and *E. faecalis*, indicating good therapeutic methods in America. Therefore, linezolid is highly effective against VRE and recommended for the infections caused by VRE.[@CIT0048],[@CIT0049] Moreover, vancomycin is useful for the treatment of VRE bacteremia in mice.[@CIT0050] However, due to linezolid's bacteriostatic activity, there are some limitations in its prescription.[@CIT0051]

Based on our review, the highest level of vancomycin resistance was observed in the Eastern Mediterranean region. This is in the main due to poor hygiene, defective health control management, insufficient control, and scarcity of antimicrobial stewardship programs in this region.[@CIT0052],[@CIT0053] However, in South-East Asian countries, the highest resistance was found in *E. faecium* isolates to linezolid. As these countries are the major importer of chickens and livestock,[@CIT0054] the excessive use of antibiotics in these products would result in the spread of multiple-drug-resistant Enterococci, which would get transmitted to humans through consumption of these products in these countries.[@CIT0055]

An increasing trend of vancomycin-resistant *E. faecium* was seen in most regions except in America. However, the trend is different for vancomycin-resistant *E. faecalis* and it was noticed to be increasing only in the Eastern Mediterranean ([Figures 1](#F0001){ref-type="fig"} and [2](#F0002){ref-type="fig"}). There are many reasons which lead to this trend in developing countries, such as poor antibiotic usage strategies,and inappropriate usage of antibiotics especially vancomycin in the treatment of Enterococcal infections.

Based on our study, resistance to tetracycline in *E. faecalis* was at the highest level. However, tetracycline is not the first-choice drug for the treatment of Enterococcal infections, it is a broad-spectrum antibiotic that can cause resistance in Enterococci during the treatment of other infections.[@CIT0056] Therefore, broad-spectrum antibiotics such as tetracycline are not recommended for treatment of Enterococcal infections.

On the other side, in African countries the highest resistance was found to ampicillin in *E. faecium*, whereas the highest resistance was observed to linezolid and gentamicin in *E. faecalis* isolates. In addition, the lowest resistance rates were detected in *E. faecalis* to ampicillin, and in *E. faecium* to both vancomycin and teicoplanin. The scarcity and extra expense of wide-spectrum antibiotics such as vancomycin led to higher prescriptions of narrow-spectrum antibiotics and thus an increased resistance to those antibiotics in this region.[@CIT0057]

For lots of antibiotics examined in our review study, the prevalence of resistance increased around the world from 2010 to 2016 in most regions. Therefore, the establishment of appropriate antibiotic usage guidelines should be essential in these countries. In contrast, decreased resistance was seen in *E. faecium* and *E. faecalis* to gentamicin and ampicillin, respectively ([Table 3](#T0003){ref-type="table"}). Probably, inappropriate consumption/prescription of antibiotics by patients/physicians and also in industries is the most important reason for increasing antibiotic resistance in Eastern Mediterranean countries. Instead, antibiotic access is restricted in other regions.

Some limitations can be introduced by the literature search procedure and we might have missed some relevant studies. Furthermore, we have excluded articles in which the total number of Enterococci was not specified. But the main strength of our study that distinguishes it from previous studies is investigating the prevalence of antibiotic resistance in two common strains of Enterococci that were isolated from blood samples in different parts of the world during 18 years.

Spit meta-regression, subgroup, meta-regression, and sensitivity analyses to detect the sources of heterogeneity, and publication bias and heterogeneity should be considered when interpreting the outcomes of the reports.

Conclusion {#S0006}
==========

Rates of resistance in South-East Asia and Eastern Mediterranean countries were at the highest level, especially for vancomycin and quinupristin/dalfopristin. There were increasing trends of antibiotic resistance in blood isolates of Enterococcus up to more than twice from 2000 to 2018. Therefore, the establishment of appropriate antibiotic usage guidelines should be essential in these countries.
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